FDA changes rule for heparin labels; Moderna says its process would underprice biopharmaceutical manufacturing;

 @EricPFierce: Happy Holidays from FDA. It extends to Dec. 18 the deadline to register API and generic drug manufacturing plants. More | Follow @EricPFierce

> The FDA is eliminating the need of healthcare providers to do dilution calculations on heparin products by requiring manufacturers to label "Heparin Lock Flush Solution, USP and Heparin Sodium Injection, USP to clearly state the strength of the entire container of the medication followed by how much of the medication is in 1 milliliter (mL)." Announcement

> A new bill has been introduced into the House of Representatives that would require compounding pharmacies to register with the FDA, and permit the agency to set production levels that would require agency inspection, although the legislation is unlikely to be taken up this year. Story

> China's Biostar Pharmaceuticals ($BSPM) has a new one-year, $8 million contract with China's Xijing Military Hospital to manufacture 16 drugs. Item

> German manufacturer Sanner, which makes plastic packaging and components, is modernizing its plant in Bensheim. Item

> Boehringer Ingelheim Biopharmaceuticals has a new deal to manufacture products for Apexigen, an emerging U.S. company working on therapeutic monoclonal antibodies. Story

And Finally... Moderna Therapeutics says its new process for treating patients with therapeutic proteins made in their own bodies could replace the need for biomanufacturing plants. Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.